New CAR T-Cell therapy takes on Hard-to-Treat myeloma
NCT ID NCT07399444
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The study will enroll 38 adults and primarily check for safety and the right dose, while also measuring how long the modified cells last in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LVIVO-TaVec400 (a CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If it works, this could point toward a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong
This is a very early, small trial (38 people) focused on safety and dosing. It may not lead to an effective treatment, and CAR T-cell therapies can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact